Table 5 illustrates current studies assessing the combination of checkpoint inhibition with anti-HER2 therapies. For a more comprehensive review of the future of checkpoint inhibitors in HER2-positive breast cancer, see the review by Agostinetto et al. [98]. This evidence concerns the gene ERBB2 and breast cancer.